The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its second quarter 2024 investor ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

周一，Canaccord Genuity重申了Exact Sciences Corporation (NASDAQ:EXAS)的买入评级，并维持75美元的目标价。这一背书是在该公司在2024年欧洲医学肿瘤学会（ESMO）大会上宣布其基于血液的结直肠癌（CRC）筛查测试的新性能数据之后做出的。 这项旨在提高新型生物标志物特异性的测试显示，对CRC的检测敏感性为88%，对进展性腺瘤（AA）的敏感性为3 ...